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Brief Technique ReportsIn 2009, we2 published the results of an exhaustive re-
view of the Food and Drug Administration (FDA)Manufac-
turer and User Facility Device Experience (MAUDE)
database regarding the incidence of reported adverse events
after Amplatzer device placement. In this review, we found
an increasing number of events reported over a 5.5-year
period, equivalent estimated mortality for device placement
compared with Society of Thoracic Surgeons database
surgical closure data, and a much higher need for operation
and operative mortality per adverse event for device closure
compared with surgical closure. After publication of these
data, wewere contacted by representatives of AGAMedical
Association, and their concerns regarding possible interpre-
tations of our results led to a clarification letter in a subse-
quent issue.3 Since that time we have been also contacted
by the FDA, where an updated data mining project is sup-
posed to be ongoing to further observe the trends in reported
complications.
Although AGA Medical has made honest attempts at
good faith reporting of ongoing results, we continue to
believe that a mandatory user registry, identical to what
surgeons use for ventricular assist devices, would be useful.
The current case report indicates that the long-term compli-
cation profile of this device is still unknown. A closer look
at the present report also reveals other interesting points that
echo the MAUDE registry findings. The fact that the patient
presented with new-onset arrhythmia 10 days after device
placement is not insignificant inasmuch as arrhythmia was
listed as an independent complication of device placement
and also was found as a warning sign of device emboliza-
tion, particularly into the right ventricle.2 New-onset ar-
rhythmias in a patient with an Amplatzer device should
be taken seriously, including an urgent echocardiographic
assessment.From the Mount Sinai Medical Center, New York, NY.
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The Journal of Thoracic and CaThe development of chest pain 1 month before the tam-
ponade episode may also be of relevance. The actual mech-
anism of the erosion of this device has been hotly debated,
but it seems that a gradually progressing erosion process is
a real possibility despite the manufacturer’s recommenda-
tions. Taggart and associates1 point out that ‘‘most reported
cases occur within 72 hours of placement,’’ but our
MAUDE data show that 24 of 51 known perforations
occurred greater than 24 hours from placement, with 8
occurring at 1 to 6 months, 2 at 6 months to 1 year, and at
3 greater than 1 year. The sites of erosion included various
combinations of atrium and/or aorta in the FDA reports, and
the left atrium was the common site of atrial level perfora-
tion. Until the mechanism of erosion and its relationship to
sizing and time after placement is better understood, we
cannot speculate on individual patient susceptibility.
The increasing number of reported adverse events with
the Amplatzer device may simply reflect an increase in
the number of devices placed. It is also possible that the
known events are just the ‘‘tip of the iceberg’’ with a con-
stant hazard function for erosion that exists over the lifetime
of the patient. The only way to get real answers to these
important issues is to actively collect short-term outcome
data and to continue active surveillance of these devices.
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EXCOR ventricular assist device in small pediatric patientsKhanh Nguyen, MD, New York, NYThe Berlin Heart EXCOR (Berlin, Germany) ventricular as-
sist device has been used with increasing frequency in youn-
ger pediatric patients. The smallest available blood pump has
a 10-mL volume, and the smallest outflow cannula tip is 3
mm in diameter. The cannula has a 90-degree angulation
with a flanged tip for sewing to the ascending aorta or main
pulmonary artery. There is a short, grooved extension from
the flange in this design. During a typical cannula insertion,
a side-biting clamp is placed on the aorta and the cannula
is anastomosed to a matching arteriotomy while the patientrdiovascular Surgery c Volume 142, Number 1 223
FIGURE 1. Guiding stay sutures ensure the tip of cannula completely in-
side the graft. FIGURE 2. Silk ligature secures the cannula to the graft.
Brief Technique Reportsis on cardiopulmonary bypass. The common problem en-
countered during this maneuver stems from matching a rigid
cannula circular tip to an almost slit-like aortotomy. Small
tears likely occur along the aortic suture line, resulting in
bleeding. We present a technique that simplifies this step of
the procedure and helps in hemostasis.
CLINICAL SUMMARY
The patient was a 19-month-old girl, weighing 8 kg, with
a diagnosis of Shone syndrome. She had previously
undergone aortic coarctation resection followed by 2 mitral
valve repairs. The patient had worsening of mitral stenosis
and an increase in pulmonary vascular resistance. She was
considered for a cardiac transplantation, and a decision
was made to use a Berlin Heart EXCOR biventricular assist
device as a bridge. The bridge would lower the pulmonary
vascular resistance and make her a transplant candidate.
After routine preparation, the patient was placed on car-
diopulmonary bypass using normothermia and bicaval can-
nulation. Because of significant mitral stenosis, a left atrial
inflow cannula was placed instead of an apical one. A size
10 polytetrafluoroethylene (PTFE) graft (GORE-TEX;
WL Gore & Associates, Flagstaff, Ariz) was anastomosed
to the ascending aorta using a side-biting clamp and a run-
ning 6-0 PTFE suture. The suture line was further sealed
with a tissue sealant before releasing the side-biting clamp.
The graft was temporarily clamped. A 6-mm outflow can-
nula was introduced through the anterior upper abdominal
wall and positioned. The PTFE graft was trimmed to
produce an optimal height to avoid cannula compression
of the right ventricle. Four simple anchoring sutures were
passed through the graft and the flange of the cannula
(Figure 1). Once the tip of the cannula was placed inside
the graft, the sutures were tied, ensuring the edge of the graft
was flushed with the flange. A number 2 silk ligature was
placed and tied at the groove of the tip of the cannula224 The Journal of Thoracic and Cardiovascular Surg(Figure 2). The placement of the right side assist device
was performed in a routine manner. Once connected and
de-aired, the devices were activated and the chest was
closed in routine fashion. With this less than 2-cm graft
extension, the cannulas’ exit sites through the upper abdom-
inal wall remained unchanged because the length of the aor-
tic cannula was minimally altered. The pump function was
optimal and hemostasis was excellent, with little bleeding
in the operating room and minimal chest tube output in
the intensive care unit. The child received a heart after
5 weeks on the device. At the explantation of the ventricular
assist device, there was a smooth pseudo-intima covering
the graft lumen with no evidence of clot formation.DISCUSSION
The technique described provides a simple and reliable
method for placement of Berlin Heart EXCOR arterial out-
flow cannulas in small children.1,2 It is not uncommon to see
bleeding from tearing an aortic suture line while trying to
anastomose a rigid circular cannula tip to a slit-like aortot-
omy. The graft is easily placed and ensures good positioning
of the cannula to avoid right ventricle compression and ten-
sion on the suture line.
CONCLUSIONS
Bleeding through needle holes, as commonly seen with
PTFE grafts, can be minimized using PTFE sutures and
tissue sealants.
References
1. Malaisrie SC, Pelletier MP, Yun JJ, Sharma K, Timek TA, Rosenthal DN, et al.
Pneumatic paracorporeal ventricular assist device in infants and children: initial
Stanford experience. J Heart Lung Transplant. 2008;27:173-7.
2. Hetzer R, Alexi-Meskishvili V, Weng Y, H€ubler M, Potapov E, Drews T, et al. Me-
chanical cardiac support in the young with the Berlin Heart EXCOR pulsatile ven-
tricular assist device: 15 years’ experience. Semin Thorac Cardiovasc Surg Pediatr
Card Surg Annu. 2006;99-108.ery c July 2011
